U
EGRX

UBS’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

UBS’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$12K Sell
938
-1,174
-56% -$14.6K ﹤0.01% 8646
2014
Q2 		$30K Buy
+2,112
New +$24.1K ﹤0.01% 7560

Other funds holding EGRX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

UBS's EGRX Position: Q3 2014 in Review

UBS reduced its Eagle Pharmaceuticals, Inc. (EGRX) stake by 56% in Q3 2014, selling an estimated $14.6K and leaving 938 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #8646.

UBS first reported a position in EGRX in Q2 2014 and has held it in 2 quarters since. The position peaked at $30K in Q2 2014. 27 funds tracked by Wall St. Rank hold EGRX as of Q3 2014.

  • UBS held 938 shares of Eagle Pharmaceuticals, Inc. worth $12K as of Q3 2014.
  • UBS sold 1,174 Eagle Pharmaceuticals, Inc. shares in Q3 2014, an estimated $14.6K.
  • Eagle Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8646 holding.
  • UBS first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2014 and has held it in 2 quarters since.
  • UBS's Eagle Pharmaceuticals, Inc. position peaked at $30K in Q2 2014.
  • 27 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.